Key Highlights
- PharmAlliance strengthens global operations with the acquisition of CHEORS, enhancing launch and commercialization services.
- This marks the third strategic acquisition by PharmAlliance under Waud Capital Partners, following BioBridges and Monitorforhire.
- CHEORS brings specialized skills in economic modeling, HTA submissions, and RWE analysis, critical for lifecycle management in drug development.
Source: Business Wire
Notable Quotes
- “CHEORS’ excellent reputation and unique approach is an important next step in the expansion of the PharmAlliance portfolio,” – Mark Bouck, Chairman & CEO at PharmAlliance and BioBridges
- “From the outset, the synergies between CHEORS and PharmAlliance have been very attractive… positioning us to make a significant impact,” – Shalini Bagga, PhD, President at CHEORS
SoHC's Take
The acquisition of CHEORS by PharmAlliance is a strategic move that reflects the growing importance of integrated services in the pharmaceutical and biotechnology sectors. By incorporating CHEORS’ expertise in health economics and outcomes research (HEOR) and market access, PharmAlliance is not only broadening its service portfolio but also enhancing its ability to support drug and device development from conception to commercialization. This acquisition could significantly boost PharmAlliance’s position as a leader in the life sciences services industry, leveraging CHEORS’ robust analytical capabilities and global reach to meet diverse client needs effectively.
